← Back to all signals
RESEARCH PAPER ANALYSIS

Efficacy of repeated external cueing training on freezing of gait and gait performance in Parkinson's disease: a systematic review and meta-analysis.

AI interpretation is pending for this paper.

PMID42212000
JournalFrontiers in aging neuroscience
Publication Date2026-01-01
Ingested2026-05-29 04:00 PM
EXECUTIVE SUMMARY

What the AI sees

Not AI summarized yet.

WHY IT MATTERS

Research significance

Pending deeper interpretation.

ABSTRACT

Source abstract

BACKGROUND: Freezing of gait (FOG) is a disabling gait disturbance in Parkinson's disease (PD) that responds poorly to pharmacological treatment. External cueing has been proposed as a non-pharmacological strategy to improve gait and mobility; however, the effectiveness of repeated external cueing training on FOG-related outcomes remains uncertain, particularly across different cueing modalities. METHODS: We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs), with a specific focus on repeated external cueing interventions (≥2 weeks). PubMed, Web of Science, Embase, the Cochrane Library, CNKI, Wanfang, and VIP databases were searched from inception to November 10, 2025. RCTs evaluating external cueing interventions in individuals with PD were included. Primary outcomes were FOG severity assessed by the Freezing of Gait Questionnaire (FOGQ) or New FOGQ (NFOGQ). Secondary outcomes included Timed Up and Go (TUG), MDS-UPDRS part III, and Berg Balance Scale (BBS). Risk of bias was assessed using ROB 2.0, and evidence certainty using GRADE. RESULTS: Nine RCTs involving patients with PD were included. Pooled analysis showed no statistically significant reduction in FOG severity following external cueing interventions compared with control conditions (SMD = -0.30, 95% CI: -0.68 to 0.09), with substantial heterogeneity. In contrast, external cueing significantly improved functional mobility as measured by the TUG test (SMD = -0.65, 95% CI: -1.15 to -0.15), although heterogeneity remained high. No consistent benefits were observed for overall motor symptoms or balance outcomes. Exploratory analysis incorporating short-term follow-up data suggested a modest improvement in FOG severity; however, these findings should be interpreted with caution due to persistent heterogeneity. The certainty of evidence for all outcomes was rated as low according to the GRADE framework. The observed heterogeneity was likely attributable to variations in intervention protocols, cueing modalities, and outcome assessment methods. CONCLUSION: External cueing interventions may improve functional mobility in individuals with PD, particularly for tasks involving gait initiation and turning. However, current evidence does not support consistent benefits for FOG severity, overall motor symptoms, or balance. Given the low certainty of evidence, further high-quality, multicenter RCTs with standardized outcome measures and longer follow-up are needed to clarify the clinical role of cueing-based interventions in FOG. These findings highlight important limitations in the current evidence base and provide directions for future research. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/PROSPERO/view/CRD420261280910, identifier CRD420261280910.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 The cGAS-STING-Glymphatic-gut Axis in Parkinson's disease: A proposed self-amplifying triad of Neuroinflammation and therapeutic opportunity. International immunopharmacology 91.0 2 Immunosenescence and Inflammaging as Drivers of Neurodegeneration: Cellular Mechanisms, Neuroimmune Crosstalk, and Therapeutic Implications. Cells 91.0 3 Flavonoids improve neurotransmitters for Parkinson's treatment: mechanism and therapeutic potential. Frontiers in pharmacology 88.0 4 Alpha-Lipoic Acid and Biotin in Neurodegenerative Diseases: Convergent Mechanistic Insights from Preclinical Models to Clinical Perspectives. Neurology international 78.0 5 The Gut Microbiota in Parkinson's Disease: Mechanistic Insights into Microbial-Host Interactions. Microorganisms 85.0 6 Linking inflammation, metabolic dysfunction, and neurodegeneration: a comprehensive review of TLR2 pathways in type 2 diabetes. Frontiers in clinical diabetes and healthcare 80.0 7 Neuroprotective effects of GLP-2 and a GLP-2/GIP dual receptor agonist in an MPTP-induced mouse model of Parkinson's disease. Peptides 86.0 8 TNF alpha unmasks enteric malate aspartate shuttle dysfunction bridging Parkinson disease and intestinal inflammation. Nature communications 91.5 9 Lipid Metabolism and Neurodegeneration: Mechanistic Insights and Therapeutic Targets. Ageing research reviews 82.0 10 Shared functional microbiome signatures in Parkinson's disease and constipation predominate irritable bowel syndrome despite taxonomic divergence. Brain, behavior, & immunity - health 80.0 11 Benzimidazole as a Versatile Scaffold for Developing Neurotherapeutics Against Neurodegenerative Diseases. ChemMedChem 74.0 12 Biomimicking neuromelanin reverses the gait deficits and dopaminergic neuronal loss in the Parkinson's disease. Colloids and surfaces. B, Biointerfaces 86.0 13 Neuroprotective roles of klotho: Molecular pathways and therapeutic implications for cognitive health in neurological and psychiatric diseases. Experimental physiology 84.0 14 Flavonoid Rutin Reduces Intestinal Inflammation in an Experimental Model of Parkinson's Disease. Neurotoxicity research 70.0 15 Nanostructured Lipid Carriers Enhance Brain Delivery and Antioxidant Efficacy of a Small-Molecule MAO B Inhibitor for Neurodegenerative Disease Therapy. Molecular pharmaceutics 78.0 16 Pathophysiological Role of the Gut Brain Axis in Parkinson's Disease: From Microbial Metabolites and Intestinal Permeability to Central Neuroinflammation. Current neurovascular research 86.0 17 Parkinson's Disease: From Metabolism to Genetics-A Comprehensive Review. Current issues in molecular biology 86.0 18 Navigating the cholesterol maze: Key insights on use of statins in neurodegenerative disorders. Neuroprotection (Chichester, England) 76.0 19 Integrative network pharmacology delineates dual GPCR and non-GPCR mechanisms of blended and individual Taikong Blue lavender and Pingyin rose essential oils in neurodegenerative and psychiatric disorders. Computers in biology and medicine 65.0 20 Models of neuroprotection in Parkinson's disease: Exploring cellular, molecular, and microenvironmental targets. Experimental neurology 78.0 21 Hyaluronic acid: emerging roles and biomaterial innovations in Alzheimer's and Parkinson's disease therapy. Frontiers in pharmacology 75.2 22 Molecular mechanisms underlying Parkinson's disease and role of phytochemicals, α-synuclein, sirtuins, and incretin mimetics in potential therapy. Frontiers in pharmacology 75.0 23 Lipid droplets in neurodegenerative diseases: pathological drivers and therapeutic vulnerabilities. Cell death discovery 82.0 24 Brain-gut-microbiota axis: a review on the bidirectional regulatory mechanisms between gut microbiota and brain and their disease interactions. Frontiers in microbiology 74.0 25 Long non-coding RNAs in neurodegenerative diseases - Molecular mechanisms, liquid biopsy biomarkers, and therapeutic targets: A review. Biomolecules & biomedicine 84.0 26 Neurosyphilis and Parkinsonism: Overlapping Pathophysiology and Emerging Therapeutic Insights. Current neurovascular research 76.0 27 Molecular biochemistry of soluble epoxide hydrolase in lipid mediator pathways and neuroinflammatory responses. The Journal of steroid biochemistry and molecular biology 82.0 28 Multifaceted role of CNPY2 beyond ER stress: Disease implications and therapeutic potential. Cell stress 83.3 29 Neuroprotective Role of Exercise-based Physiotherapy Combined with Pharmacological Agents in Parkinson's Disease. Central nervous system agents in medicinal chemistry 64.0 30 Distinct metabolomic and proteomic signatures in Parkinson's disease patients with REM sleep behavior disorder. Signal transduction and targeted therapy 84.0 31 HMGB1-mediated neuroinflammation: molecular mechanisms and emerging therapeutic approaches. Inflammopharmacology 78.0 32 Beyond acid-base dyshomeostasis: Dynamic instability of neuronal lysosomal pH as a pathogenic mechanism and therapeutic target in neurological diseases. Biochemical pharmacology 88.0
Neurocompute Parkinson’s Narrative Velocity Infographic
NEUROCOMPUTE VISUAL SYSTEM

Open the Narrative Velocity Map

Explore the full Parkinson’s research intelligence diagram.

Expand Intelligence View →
Full Neurocompute Infographic